moderately significantP < 0.04
For AVR–BVC, 11.5% and 20.6% decreases were observed for control versus mild, and control versus severe SCR (moderately significant, P < 0.04 for all cases) eyes ( Fig. 4B 4).
For AVR–BVC, 11.5% and 20.6% decreases were observed for control versus mild, and control versus severe SCR (moderately significant, P < 0.04 for all cases) eyes ( Fig. 4B 4).